Study to Evaluate the Effects of MEDI6012 on Apolipoprotein B100 Metabolism

NCT03773172 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

7

Enrollment

OTHER

Sponsor class

Stopped Early termination due to COVID-19

Conditions

Cardiovascular Diseases

Interventions

DRUG: MEDI6012
DRUG: Placebo

Sponsor

Columbia University

Collaborators

[object Object]
[object Object]